A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Elagolix (Primary) ; Estradiol/norethisterone (Primary)
- Indications Menorrhagia; Uterine leiomyoma
- Focus Adverse reactions; Registrational
- Sponsors AbbVie
- 19 Jul 2024 Status changed from active, no longer recruiting to completed.
- 27 Mar 2024 Planned End Date changed from 16 Jul 2024 to 11 Jul 2024.
- 27 Mar 2024 Planned primary completion date changed from 27 Nov 2023 to 11 Jul 2024.